MSLN and sarcomatoid mesothelioma: In addition, CAR-T cells targeting podoplanin, a transmembrane glycoprotein highly expressed in sarcomatoid mesothelioma, have shown antitumor activity in preclinical glioblastoma models [195] and may represent a valuable therapeutic option for sarcomatoid mesothelioma, which typically expresses high levels of this surface protein, but low levels of mesothelin.